Objective:The liver is the most common metastatic site in advanced colorectal cancer.Most patients with colorectal cancer liver metastasis(CRLM)cannot benefit from currently available treatment.Patient-derived xenogra...Objective:The liver is the most common metastatic site in advanced colorectal cancer.Most patients with colorectal cancer liver metastasis(CRLM)cannot benefit from currently available treatment.Patient-derived xenograft(PDX)models with defined molecular signatures are attractive preclinical models and essential for preclinical studies.展开更多
文摘Objective:The liver is the most common metastatic site in advanced colorectal cancer.Most patients with colorectal cancer liver metastasis(CRLM)cannot benefit from currently available treatment.Patient-derived xenograft(PDX)models with defined molecular signatures are attractive preclinical models and essential for preclinical studies.